Institute of Clinical Medicine, Department of Pediatrics, University of Eastern Finland, Kuopio, Finland.
Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland.
BMC Pediatr. 2024 Aug 6;24(1):503. doi: 10.1186/s12887-024-04982-x.
The Finnish treatment guidelines for sore throat were updated in June 2020. The aim of this study was to determine how the publication of these guidelines affected the treatment of pediatric patients, particularly through the use of the Centor criteria, C-reactive protein tests, and microbiological testing in the diagnosis of Group A β-hemolytic streptococci tonsillitis.
We conducted a retrospective single-center before-and-after cohort study in Finland from 2019 to 2022. We included all patients who visited the pediatric emergency department and were diagnosed with tonsillitis or pharyngitis.
We included 246 patients who were admitted before the guidelines were updated and 219 patients after. Only two patients in the after group had a Centor score reported in their patient records. Rapid antigen tests were administered to 231 patients (93.9%) before the update and 202 patients (92.2%) after (proportion difference of 1.7%, CI -3.0-6.6%). C-reactive protein was taken from 193 patients (78.5%) before the update and 189 patients (86.3%) after (proportion difference of 7.8%, CI 0.1-14.7%).
Centor scores were not used as recommended in the guidelines and did not impact the use of microbiological or C-reactive protein testing. More education and examining the preconceptions of health care personnel is required to implement the updated treatment guidelines in clinical practice.
芬兰的咽痛治疗指南于 2020 年 6 月更新。本研究旨在确定这些指南的发布如何影响儿科患者的治疗,特别是通过使用 Centor 标准、C 反应蛋白检测和微生物检测来诊断 A 组β-溶血性链球菌扁桃体炎。
我们在芬兰进行了一项回顾性单中心前后队列研究,时间为 2019 年至 2022 年。我们纳入了所有因咽痛或咽炎就诊并被诊断为扁桃体炎或咽炎的患者。
我们纳入了更新指南前的 246 名患者和更新后 219 名患者。在后一组患者的病历中,仅有 2 名患者报告了 Centor 评分。在更新前,231 名患者(93.9%)接受了快速抗原检测,更新后有 202 名患者(92.2%)接受了检测(比例差异为 1.7%,CI-3.0-6.6%)。在更新前,193 名患者(78.5%)接受了 C 反应蛋白检测,更新后有 189 名患者(86.3%)接受了检测(比例差异为 7.8%,CI0.1-14.7%)。
指南中推荐的 Centor 评分并未得到应用,也未影响微生物或 C 反应蛋白检测的应用。需要进一步加强教育,并检查医疗保健人员的固有观念,以便在临床实践中实施更新后的治疗指南。